Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Decreases By 40.5%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 92,200 shares, a decrease of 40.5% from the January 31st total of 154,900 shares. Based on an average daily volume of 370,300 shares, the short-interest ratio is presently 0.2 days. Currently, 5.3% of the company’s stock are short sold.

Avenue Therapeutics Price Performance

ATXI stock traded down $0.00 during trading hours on Tuesday, reaching $1.01. 17,802 shares of the stock were exchanged, compared to its average volume of 135,700. The firm’s 50-day moving average is $1.59 and its 200-day moving average is $2.02. Avenue Therapeutics has a 12 month low of $0.99 and a 12 month high of $15.00. The company has a market cap of $2.07 million, a price-to-earnings ratio of 0.05 and a beta of -0.28.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new stake in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned about 2.00% of Avenue Therapeutics at the end of the most recent quarter. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.